Stay updated on Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial

Sign up to get notified when there's something new on the Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the pharmacokinetics (PK) evaluation, safety, tolerability, and immune response assessment of Dolutegravir (DTG) when used concurrently with optimized background therapy (OBT) in HIV-1 infected infants, children, and adolescents.
    Difference
    0.1%
    Check dated 2024-06-06T14:25:16.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying requirements such as confirmed HIV-1 infection and prior ARV treatment history. This change provides more specific information about the health conditions and prior treatments needed for study participation.
    Difference
    27%
    Check dated 2024-05-22T21:25:16.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:32:15.000Z thumbnail image

Stay in the know with updates to Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial page.